Market Signal Briefing

Nextech3D.AI (CSE:NTAR, OTCQX:NEXCF) CEO Evan Gappelberg spoke with Proactive about how artificial intelligence (AI) is reshaping the global events industry and the company’s latest developments in delivering a fully integrated AI-powered event tech platform. 

Gappelberg said, “AI is no longer just a nice to have. It's a new operating system for the global events industry.”  

He explained that Nextech3D.ai is deploying AI to streamline event operations, from registration and ticketing to matchmaking, floor mapping, and analytics. 

The company’s recent acquisition of Eventdex, alongside integration with its existing Map D platform, forms the foundation for this system.  

Features include AI-powered business matchmaking that books attendees' calendars based on their goals and behavior, as well as a multilingual AI assistant that acts as a 24/7 digital concierge.  

The assistant provides real-time guidance and information to attendees and also serves organizers with actionable data insights. 

Wayfinding and context-aware assistance are also part of the platform, reducing the need for on-site help desks.  

Gappelberg emphasized the mission to build “the world’s most intelligent, automated event tech platform,” and noted that blockchain-based ticketing is the next area of focus. 

The rollout is beginning with existing clients from both the Eventdex and Map D platforms, with plans to expand functionality over time. 

RADNOR, Pa., Oct. 18, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Fortinet, Inc. (“Fortinet”) (NASDAQ: FTNT) on behalf of those who purchased or otherwise acquired Fortinet common stock between November 8, 2024, and August 6, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is November 21, 2025.

CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
If you suffered Fortinet losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/fortinet-inc?utm_source=Globe&mktm=PR

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected].

DEFENDANTS’ ALLEGED MISCONDUCT:
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Fortinet knew that the company’s refresh cycle would never be as lucrative as they represented because it consisted of old products that were a “small percentage” of Fortinet’s business; (2) Fortinet misrepresented and concealed that the company did not have a clear picture of the true number of FortiGate firewalls that could be upgraded; (3) while telling investors that the refresh would gain momentum over the course of two years, Fortinet misrepresented and concealed that the company had aggressively pushed through roughly half of the refresh in a period of just a few months, by the end of second quarter 2025; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/2-aYECTS09c

THE LEAD PLAINTIFF PROCESS:
Fortinet investors may, no later than November 21, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages Fortinet investors who have suffered significant losses to contact the firm directly to acquire more information.

CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/fortinet-inc?utm_source=Globe&mktm=PR

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:     

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of LGCY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of PAGP, EPD, WES either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Tronox (TROX) To Contact Him Directly To Discuss Their Options

If you purchased or acquired common stock in Tronox between February 12, 2025, to July 30, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) --

What’s Happening:

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Tronox Holdings plc (“Tronox” or the “Company”) (NYSE:TROX) in the United States District Court for the District of Connecticut on behalf of all persons and entities who purchased or otherwise acquired Tronox common stock between February 12, 2025, to July 30, 2025, both dates inclusive (the “Class Period”).Investors have until November 3, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Allegation Details:

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Tronox’s ability to forecast the demand for its pigment and zircon products or otherwise the true state of its commercial division, despite making lofty long-term projections, Tronox’s forecasting processes fell short as sales continued to decline and costs increased, ultimately, derailing the Company’s revenue projections.On July 30, 2025, Tronox announced its financial results for the second quarter of fiscal 2025, revealing a significant reduction in TiO2 sales for the quarter. The Company attributed the decline to “softer than anticipated coatings season and heightened competitive dynamics.” As a result of the setback in sales, defendants revised the Company’s 2025 financial outlook lowering its full-year revenue guidance and reducing its dividend by 60%.Following this news, Tronox’s common stock declined dramatically. From a closing market price of $5.14 per share on July 30, 2025, Tronox’s stock price fell to $3.19 per share on July 31, 2025, a decline of about 38% in the span of just a single day.
Next Steps:

If you purchased or otherwise acquired Tronox shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Palantir Technologies Inc. ("Palantir" or the "Company") (NASDAQ: PLTR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Palantir and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 3, 2025, media outlets reported that an internal U.S. Army memo described the NGC2 platform – a battlefield communication system developed by Palantir and Anduril Industries – as a "very high risk" due to security vulnerabilities that could allow adversaries to gain "persistent undetectable access" to the system. 

On this news, Palantir's stock price fell $13.98 per share, or 7.47%, to close at $173.07 per share on October 3, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Quantum Corporation ("Quantum" or the "Company")(NASDAQ: QMCO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Quantum and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 3, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Quantum securities during the Class Period. A copy of the Complaint can be obtained at  www.pomerantzlaw.com .  

[Click here for information about joining the class action]

On June 30, 2025, Quantum disclosed in a filing with the U.S. Securities and Exchange Commission ("SEC") that it would postpone the filing of its Annual Report because it was in the process of reviewing its revenue recognition accounting practices. 

 On this news, Quantum's stock price fell $1.00 per share, or 10.03%, to close at $8.97 per share on July 1, 2025. 

Then, on August 8, 2025, Quantum filed a report with the SEC, announcing that the Company's financials for the third quarter of 2024 could not be relied upon and would be restated to show a new decrease of approximately $3.9 million in revenue, and that there were deficiencies in the Company's internal control over financial reporting and the Company's disclosure controls and procedures that constituted material weaknesses as of December 31, 2024 and March 31, 2025. 

On this news, Quantum's stock price fell $0.14 per share, or 1.85%, to close at $7.43 per share on August 11, 2025. 

Finally, on August 18, 2025, Quantum announced the resignation of its Chief Financial Officer Lewis Moorehead amid an internal accounting review related to its revenue recognition practices. 

On this news, Quantum's stock price fell $0.61 per share, or 8.2%, to close at $6.83 per share on August 19, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether LifeMD and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until October 27, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired LifeMD securities during the Class Period. A copy of the Complaint can be obtained a t www.pomerantzlaw.com .        

[Click here for information about joining the class action]

On August 5, 2025, after the market closed, the Company issued a press release entitled "LifeMD Reports Second Quarter 2025 Results."  This announcement quoted Chief Financial Officer Marc Benathen as stating that due to "some temporary challenges facing our Rex MD business," which he claimed were "largely resolved," that the Company was "revising our full year 2025 guidance for revenue and adjusted EBITDA to reflect the full-year impact of these issues, while still anticipating strong year-over-year growth in both metrics." 

On this news, LifeMD's stock price fell $5.31 per share, or 44.85%, to close at $6.53 per share on August 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against VF Corporation ("VFC" or the "Company") (NYSE: VFC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

The class action concerns whether VFC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

You have until November 12, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired VFC securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com .

[Click here for information about joining the class action]

On May 21, 2025, VFC reported its fourth quarter and full-year fiscal 2025 financial results, highlighting a significant decline in the growth trajectory for its Vans brand, which fell from an 8% loss in the previous quarter to a 20% loss in the fourth quarter. VFC described these results and below-expectation guidance as "a direct effect of deliberately reduced revenue to eliminate unprofitable or unproductive businesses." 

Following this news, VFC's stock price fell $2.21 per share, or 15.8%, to close at $12.15 per share on May 21, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980 

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-08010, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Jasper securities between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Jasper securities during the Class Period, you have until November 18, 2025 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible Urticaria ("CIndU"), and Asthma. The Company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor ("SCF") from binding to and signaling through the CD117 ("c-Kit") receptor on mast and stem cells. According to Jasper, the "SCF/c-Kit pathway is a survival signal for mast cells and [the Company] believe[s] that blocking this pathway may lead to depletion of these cells throughout the body, including in the lungs and in the skin, which could lead to significant clinical benefit for patients with mast-cell driven diseases such as asthma and chronic urticarias" and "[t]o that end, [Jasper is] focusing on advancing a portfolio of clinical programs in mast cell driven diseases." In 2024, to "strengthen [its] balance sheet and support development of briquilimab," Jasper completed an oversubscribed $50 million financing "with a syndicate of leading life science investors," purportedly "extending [its] cash runway through the third quarter of 2025."

In November 2023, the Company commenced a Phase 1b/2a clinical study of subcutaneous briquilimab for the treatment of CSU (the "BEACON Study"). When announcing the first patient dosing in the BEACON Study, Jasper's Chief Executive Officer Defendant Ronald Martell stated, in relevant part, that he was "confident in the ability of our clinical organization to continue to execute at a high level as we advance briquilimab into clinical trials in CIndU and other mast cell-driven diseases." In December 2024, the Company commenced a Phase 1b/2a clinical study evaluating briquilimab in allergic asthma (the "ETESIAN Study"). In addition, Jasper has attempted to develop briquilimab as a one-time conditioning therapy for severe combined immunodeficiency ("SCID") patients undergoing a second stem cell transplant.

Under the Drug Supply Chain Security Act —a law enacted by Congress in 2013 designed to improve and ensure the safety of the U.S pharmaceutical supply chain—all prescription drugs must be labeled with a unique product identifier that includes, among other things, a "lot number." Drug "lots" are batches of a product that are manufactured, processed, packaged, or stored under the same conditions. If a medication is compromised, pharmaceuticals companies can use lot numbers to trace the affected batches and alert healthcare providers.

According to the Company, "[t]he manufacture of pharmaceuticals is subject to extensive [current Good Manufacturing Practices ("cGMP")] regulations, which impose various procedural and documentation requirements and govern all areas of record keeping, production processes and controls, personnel and quality control." Because Jasper does not currently own or operate any manufacturing facility, the Company relies on third-party contract manufacturing organizations to produce its drug candidates in purported "accordance with cGMP regulations for use in [its] clinical studies."

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (ii) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company's products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; (iv) accordingly, the Company's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On July 7, 2025, Jasper issued a press release reporting updated data from the BEACON Study. The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed with drug from the lot in question," that "[t]he Company is investigating the drug product lot in question and expects to have the results of that investigation in the coming weeks," and that Jasper was "taking steps to ensure that drug product from the lot in question is returned to the Company and that sites have drug product from other lots to continue dosing." Further, the press release revealed that the Company "has also determined that the drug product lot in question was used to treat participants enrolled in the ETESIAN [Study]. As a result, and in order to focus resources on advancing briquilimab in CSU, the Company is halting the study and pausing development in asthma." Finally, the press release stated that "the Company is halting development in SCID" and, contrary to its prior representation of having a strong balance sheet and a cash runway extending "through the third quarter of 2025," that Jasper "will be implementing a number of other cost cutting measures including a potential restructuring, to extend runway and reduce expenses."

On this news, Jasper's stock price fell $3.73 per share, or 55.1%, to close at $3.04 per share on July 7, 2025.

Market analysts were quick to comment on the Company's announcement. For example, on July 7, 2025, BMO Capital Markets published a report downgrading Jasper to market perform and lowering its price target from $6.77 per share to $4.00 per share (the "BMO Report"). The BMO Report stated, in relevant part, that "potential Briquilimab drug lot issues, coupled with existing uncertainty around dose-response [], will pressure the [Jasper] story moving forward" given, among other things, Jasper's "financing overhang" and market competition.

After the end of the Class Period, on July 9, 2025, the Company issued a press release entitled "Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway." The press release revealed that Jasper was reducing its workforce by approximately 50%, that "[i]n order to focus resources on the development of briquilimab in chronic urticaria, Jasper is halting its other clinical and preclinical programs," and that Defendant Edwin Tucker was departing his role as the Company's Chief Medical Officer effective August 1, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Quanex Building Products Corporation ("Quanex" or the "Company") (NYSE: NX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Quanex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 18, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Quanex securities during the Class Period. A copy of the Complaint can be obtained at  www.pomerantzlaw.com .        

[Click here for information about joining the class action]

On September 4, 2025, after the market closed, Quanex announced its financial results for the third quarter of its 2025 fiscal year.  Quanex disclosed, among other things, that ongoing "operational issues related to the legacy Tyman window and door hardware business in Mexico" had "impacted results more than expected[.]"  Quanex also disclosed that it was "adjusting for lower expected volumes and pushing oug the timing of when [it] expect[s] to realize procurement savings" from integration of the Tyman business.  Then, on September 5, 2025, Quanex held an earnings call to discuss the quarter's financial results.  During the call, Chief Executive Officer George Wilson explained that the operational challenges at Tyman "negatively impacted EBITDA in the Hardware Solutions segment by almost $5 million in the third quarter alone."  Wilson explained that the issue had been "identified midyear" and described the systems used to "anticipate and plan for tooling repairs" as significantly deficient. 

On this news, Quanex's stock price fell $2.73 per share, or 13.06%, to close at $18.18 per share on September 5, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Dow Inc. ("Dow" or the "Company") (NYSE: DOW) and certain officers. The class action, filed in the United States District Court for the Eastern District of Michigan, Northern Division, and docketed under 25-cv-12744, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Dow securities between January 30, 2025 and July 23, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Dow securities during the Class Period, you have until October 28, 2025, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Dow is an American materials science company, serving customers in the packaging, infrastructure, mobility, and consumer applications industries. Dow conducts its worldwide operations through six global businesses organized into three operating segments: (i) Packaging & Specialty Plastics, (ii) Industrial Intermediates & Infrastructure, and (iii) Performance Materials & Coatings.

Historically, Dow has touted its "industry-leading dividend," which is of particular importance to investors. On conference calls with investors and analysts, Dow's Chief Executive Officer, Defendant Jim Fitterling ("Fitterling"), has variously stated that the Company's "dividend is a key element of our investment thesis," and that "north of 65% of our owners count on that dividend."

Notwithstanding an ongoing slump in the materials science industry, as well as the recent onset of tariff-related market uncertainties, at all relevant times, Defendants represented that Dow was well positioned to weather macroeconomic and tariff-related headwinds while maintaining sufficient levels of financial flexibility to support the Company's lucrative dividend. Specifically, Defendants cited various purported strengths and advantages unique to Dow in its industry, including, inter alia, the Company's purported "differentiated portfolio," "cost-advantaged footprint," and "industry-leading flexibility to navigate global trade dynamics."

Throughout the Class Period, Defendants made materially false and misleading statements regarding Dow's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Dow's ability to mitigate macroeconomic and tariff-related headwinds, as well as to maintain the financial flexibility needed to support its lucrative dividend, was overstated; (ii) the true scope and severity of the foregoing headwinds' negative impacts on Dow's business and financial condition was understated, particularly with respect to competitive and pricing pressures, softening global sales and demand for the Company's products, and an oversupply of products in the Company's global markets; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On June 23, 2025, BMO Capital downgraded its recommendation on Dow to "Underperform" from "Market Perform" while also cutting its price target on the Company's stock to $22.00 per share from $29.00 per share, citing sustained weakness across key end markets and mounting pressure on the Company's dividend.

On this news, Dow's stock price fell $0.89 per share, or 3.21%, to close at $26.87 per share on June 23, 2025.

Then, on July 24, 2025, Dow issued a press release reporting its financial results for the second quarter of 2025. Therein, Dow reported a non-GAAP loss per share of $0.42, significantly larger than the approximate $0.17 to $0.18 per share loss expected by analysts. Dow also reported net sales of $10.1 billion, representing a 7.3% year-over-year decline and missing consensus estimates by $130 million, "reflecting declines in all operating segments." The Company further reported, inter alia, that "[s]equentially, net sales were down 3%, as seasonally higher demand in Performance Materials & Coatings was more than offset by declines across the other operating segments." Defendant Fitterling blamed these disappointing results on "the lower-for-longer earnings environment that our industry is facing, amplified by recent trade and tariff uncertainties," while providing a dour outlook marked by "signs of oversupply from newer market entrants who are exporting to various regions at anti-competitive economics."

In a separate press release issued the same day, Dow revealed that it was cutting its dividend in half, from $0.70 per share to only $0.35 per share, citing the need for "financial flexibility amidst a persistently challenging macroeconomic environment."

Following these disclosures, Dow's stock price fell $5.30 per share, or 17.45%, to close at $25.07 per share on July 24, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Gold has continued to climb. We speak to experts about the best ways to invest in gold.

ICICI Bank Limited (NYSE:IBN) Q2 2026 Earnings Call October 18, 2025 7:30 AM EDT

Company Participants

Sandeep Bakhshi - MD, CEO & Executive Director
Anindya Banerjee - Group CFO & Head of Investor Relations

Conference Call Participants

Mahrukh Adajania - Nuvama Wealth Management Limited, Research Division
Harsh Modi - JPMorgan Chase & Co, Research Division
Anand Swaminathan - BofA Securities, Research Division
Kunal Shah - Citigroup Inc., Research Division
Rikin Shah - IIFL Research
Piran Engineer - CLSA Limited, Research Division
Chintan Joshi

Presentation

Operator

Ladies and gentlemen, good day, and welcome to the Q2 FY '26 Earnings Conference Call of ICICI Bank. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Sandeep Bakhshi, Managing Director and Chief Executive Officer of ICICI Bank. Thank you, and over to you, sir.

Sandeep Bakhshi
MD, CEO & Executive Director

Thank you. Good evening to all of you, and welcome to the ICICI Bank earnings call to discuss the results for Q2 of financial year 2026. Joining us today on this call are Sandeep Batra, Rakesh, Ajay, Anindya and Abhinek.

At ICICI Bank, our strategic focus continues to be on growing profit before tax, excluding treasury, through the 360-degree customer-centric approach and by serving opportunities across ecosystems and micro markets. We continue to operate within the framework of our values to strengthen our franchise.

Maintaining high standards of governance, deepening coverage and enhancing the delivery capabilities with a focus on simplicity and operational resilience are key drivers for our risk-calibrated profitable growth.

The profit before tax, excluding treasury, grew by 9.1% year-on-year to INR 161.64 billion in this quarter. The core operating profit increased by 6.5% year-on-year to INR 170.78 billion in this quarter. The profit after tax grew by 5.2% year-on-year to INR 123.59 billion in this quarter.

Recommended For You

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 60% and reduced the risk of death by 50% when given before and after surgery (radical cystectomy) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible f.

First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer Unprecedented survival results from pivotal Phase 3 EV-303 trial show potential for PADCEV plus KEYTRUDA to redefine standard of care TOKYO and NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as KEYNOTE-905) for PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA™ (pembrolizumab), a PD-1 inhibitor. The study evaluated the combination in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or declined cisplatin-based chemotherapy.

Jordan Blashek says A.I. will face pressure from rising capex spending and, more importantly, energy consumption.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Barstool Sports founder Dave Portnoy has revealed plans to buy XRP again after selling earlier in the year, just before the altcoin reached a new all-time high (ATH). He also mentioned the price level that he is looking at for the altcoin to dip to before he makes another purchase.

Dave Portnoy Says He Will Buy XRP When This Happens
In an X post, the Barstool founder said he will go ‘bonkers’ if the altcoin dips below $2.20, indicating plans to buy it on that dip. This came during a Q&A on X when a follower asked him if he had bought XRP again since he last sold it all.

Portnoy responded that he hadn’t bought since then, but that he has been checking the price “every 5 seconds” and plans to do so if it dips below $2.20. As CoinGape reported, the Barstool founder revealed in July earlier this year that he sold the altcoin at $2.40, just before it rose to a new all-time high (ATH) of $3.60.

He made the revelation remorsefully back then, stating that he wanted to “cry,” considering that he would have made millions. However, since then, XRP has been on a downtrend, down over 32% in the last 90 days.

The latest crash for the XRP has come amid the rising trade tensions between the U.S. and China, with other crypto assets, including Bitcoin, also on the decline. Notably, the altcoin dipped below the $2.20 level Dave Portnoy mentioned last week, after Trump announced 100% tariffs on China.

Another Dip Below $2.2 Still Likely
Crypto analyst CasiTrades indicated that the XRP price is likely to drop below $2.2 soon. She stated that a retest of the .618 retracement around $1.46 or even the golden pocket near $1.35 is “very possible” for the next wave down, as these levels are where multiple technicals align.

🚨XRP Pauses After the Chaos. Wave 5 or the Start of A New Trend? 🚨

After last Friday’s massive wipeout, the market rebounded nicely, but is now stalling… This is to be expected after such an extreme move. In EWT, this kind of pause is a Wave 4. The market consolidates and… pic.twitter.com/9qYzyQ2r3T

— CasiTrades 🔥 (@CasiTrades) October 16, 2025

The analyst had earlier noted how the market had rebounded nicely after last Friday’s $19 billion liquidation event, but is now stalling. She explained that this is to be expected after such a sharp move to the downside. CasiTrades further described this kind of pause as a Wave 4, with the market consolidating and preparing for the final wave of the impulse.

She then mentioned that XRP could stage a massive reversal if its price targets the Wave 5 extension, macro golden retraces, and Wave 2 target. CasiTrades claimed that this could potentially start the long-awaited wave that would send the altcoin to between $6.50 and $10.

The analyst added that this is “the silver lining in all this chaos.” She explained that while the crash was devastating, it may have shifted the count from a shallow Wave 4 to a deeper macro Wave 2, which “sets up for the most powerful impulse in the cycle.”

Investment disclaimer: The content reflects the author’s personal views and current market conditions. Please conduct your own research before investing in cryptocurrencies, as neither the author nor the publication is responsible for any financial losses.

Ad Disclosure: This site may feature sponsored content and affiliate links. All advertisements are clearly labeled, and ad partners have no influence over our editorial content.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

In recent hours, 450 million Dogecoin have arrived at major crypto exchange Binance. According to Blockchain data tracker Whale Alert, 450,000,000 DOGE worth $83,403,700 were transferred from an unknown wallet to Binance.

A move to exchanges might indicate an intent to sell, although other reasons might be likely, and follows the recent volatility in the market.

Friday's sell-off saw over $1.2 billion in crypto liquidations as investors jittered over banking concerns and escalating trade tensions.

Dogecoin extended its drop amid a short-term golden cross and risk-off sentiment in the broader market, falling for the fourth consecutive day since Oct. 13 before rebounding.

HOT Stories

At the time of writing, Dogecoin was trading in green, reversing daily losses.

Dogecoin trades in greenDogecoin stabilized Friday after early volatility saw its price drop to $0.175 before recovering into a tight $0.18-$0.19 range. At the time of writing, DOGE was up 4.71% in the last 24 hours to $0.187 amid a broader crypto market recovery.

Dogecoin reached an intraday high of $0.189; in the coming sessions, it will be watched for a confirmation of $0.18 as a short-term base.

According to Ali, a crypto analyst, a breakout above $0.19 could act as a trigger for a retest of the $0.20-$0.21 zone. Ali noted the $0.19 level as being mission-critical for DOGE, as a sustained breach above it might eye $0.33 as the next stop.

Ali, in a separate tweet, noted that Dogecoin has potential to rebound with its next targets at $0.29, $0.45 and $0.86.

However, if ZEC breaks below the ascending trendline, a short-term correction toward $200–$172 remains possible before any renewed advance.

Overall, the triangle favors bulls, especially as broader accumulation persists, reinforcing trader Deer Juice’s projection of a rally toward $500 in the coming weeks.

Zcash Latest News: Do Fundamentals Support Further ZEC Upside?
Zcash’s fundamentals are looking as bullish as its technicals.

On Oct. 16, Zcash launched the Zolana bridge, a crosschain protocol connecting the Zcash, Solana, and Near networks. This integration allows users to move ZEC seamlessly onto the Solana blockchain using Near’s OmniBridge and Chain Signatures technology.

🛡️ The Zolana Bridge is live.

Your Intent: $ZEC on Solana.

Delivered: with NEAR Intents + OmniBridge powering Zcash’s $ZEC token on Solana. pic.twitter.com/cXBqgCXXTK

— NEAR Protocol (@NEARProtocol) October 16, 2025

Through the Near Intents app, users can even swap for shielded ZEC and withdraw it directly on Solana, extending Zcash’s privacy layer into the high-speed Solana DeFi ecosystem.

This marks a major step in Zcash’s interoperability strategy, positioning it as a privacy hub across multiple layer-1 chains.

The move also coincides with THORSwap’s integration of native ZEC swaps on Sept. 30, enabling direct crosschain transactions between ZEC and assets like BTC, ETH, SOL, XRP, and BNB via Maya Protocol.

An artificial intelligence (AI)  model has issued several price forecasts for XRP after it emerged that Ripple is planning to establish a treasury for the cryptocurrency.

Notably, Ripple aims to raise at least $1 billion through a special purpose acquisition company (SPAC) to fund the new XRP treasury, which will also be partially backed by its own holdings. 

The move represents one of Ripple’s most ambitious efforts to boost XRP’s liquidity and investor confidence, though the treasury’s size may influence sentiment more than it sparks an immediate price surge.

XRP price prediction 
Regarding the potential impact on price, Finbold turned to OpenAI ChatGPT, which estimated that XRP could reach between $3.30 and $3.60 within the next 6 to 12 months if the treasury formation goes as planned and market sentiment remains supportive.

Looking further ahead, the AI projects that in 12 to 24 months, assuming broader adoption and a favorable crypto bull cycle, XRP could climb to between $4 and $5.

XRP price prediction. Source: ChatGPT
However, the AI cautioned against overly bullish expectations, noting that a dramatic surge to $20 or higher would likely require major additional catalysts, such as ETF approvals, large-scale banking adoption, or significant regulatory breakthroughs.

The prediction highlighted key factors that could shape XRP’s trajectory, including the speed of the SPAC’s formation, the transparency of treasury disclosures, and broader crypto market conditions. If the treasury buys XRP aggressively, ChatGPT warned that reduced liquidity could trigger short-term price spikes but also increase volatility risks.

XRP price analysis
Meanwhile, the outlook comes as XRP faces increased bearish sentiment, reflecting broader market trends. By press time, the token was trading at $2.39, having rallied about 4% in the past 24 hours, though it remains down 3.5% on the weekly timeframe.

XRP seven-day price chart. Source: Finbold
From a technical perspective, XRP is showing weakness below both its 50-day simple moving average (SMA) of $2.85 and its 200-day SMA of $2.62, signaling a sustained bearish trend. The short-term moving average sitting well above the current price suggests downward momentum remains strong, with buyers struggling to regain control.

Meanwhile, the 14-day Relative Strength Index (RSI) at 30.25 indicates that XRP is hovering near oversold territory but still considered neutral, hinting that selling pressure may be easing slightly.

Featured image via Shutterstock

In brief
Stablecoin behemoth Tether donated $250,000 to OpenSats this week, prompting Jack Dorsey to criticize the amount of the gift.
Dorsey highlighted his own $21 million donation and drew mixed reactions from the Bitcoin community.
Udi Wertheimer later called out Dorsey over his investment in Ocean, a Bitcoin mining pool that has attracted controversy.
Sometimes it can be easier to say nothing at all. 

This week, stablecoin giant Tether announced a $250,000 donation to OpenSats to support Bitcoin developers—only for one of the world’s best-known programmers (and Bitcoin maximalists) to publicly chastise the size of the gift. 

Twitter co-founder and Square CEO Jack Dorsey lampooned the donation Thursday on X, shortly after it was touted by Tether’s CEO, Paolo Ardoino.

“Why only $250K?” Dorsey replied curtly to Ardoino.

Tether is one of the crypto industry’s most profitable companies. The USDT issuer, which posted a $13 billion profit last year, is reportedly seeking a $500 billion valuation in talks with potential investors. 

Tether said its donation to OpenSats, which funds the development of free and open-source Bitcoin software, will support the nonprofit’s operations and grant-making efforts.

A representative for the company did not respond to Decrypt’s request for comment on Dorsey’s comment, which Ardoino did not respond publicly to.

Shortly after the comment was made, however, another X user pressed Dorsey on his own financial commitment to the cause of protecting Bitcoin developers, questioning how much he had donated.

The entrepreneur immediately shot back: “Over $21 million. You?”

Indeed, OpenSats received a $21 million donation from Dorsey’s Start Small initiative in 2024. The tech billionaire has been an outspoken advocate for decentralized technology and censorship resistance for years, and one of the most famous Bitcoin backers around.

But even Dorsey was not without his detractors. Udi Wertheimer, creator of popular Bitcoin Ordinals project Taproots Wizards, at first took Dorsey’s side in the scuffle—but then turned on the Twitter inventor.

“No one should go into a pissing match with Jack when it comes to funding open-source Bitcoin development,” Wertheimer said.

The Bitcoiner went on, though, to lambast Dorsey for his investments in Ocean, a Bitcoin mining pool that previously caught heat for discouraging the processing of non-financial transactions on the Bitcoin blockchain, including the creation of NFT-like Ordinals.

“You should subtract from that number whatever the size of your Ocean investment was,” Wertheimer said of Dorsey’s philanthropic contributions. “Sadly, that capital is being actively deployed to slow down development.”

Alas, on Crypto Twitter, nobody’s perfect.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Ethereum extends rally amid $84B TVL surge – Ethereum price prediction suggests breakout potential toward $4,300 next.

Robinhood has expanded its tokenization initiative on the Arbitrum blockchain, deploying 80 new stock tokens in the past few days and bringing the total number of tokenized assets close to 500.

According to data from Dune Analytics, Robinhood has tokenized 493 assets with a total value exceeding $8.5 million. Cumulative mint volume has surpassed $19.3 million, offset by around $11.5 million in burning activity, signaling a growing but actively traded market.

Stocks account for nearly 70% of all deployed tokens, followed by exchange-traded funds (ETFs) at about 24%, with smaller allocations to commodities, crypto ETFs and US Treasurys.

The latest batch of tokenized assets includes Galaxy (GLXY), Webull (BULL), and Synopsys (SNPS), research analyst Tom Wan said. “Robinhood EU users now have a wider range of US Stocks, Equities, and ETFs, thanks to Tokenization,” he noted.

Robinhood has tokenized 493 assets. Source: Dune Analytics Blockchain-based derivatives, not real sharesIn June, Robinhood launched a tokenization-focused layer-2 blockchain built on Arbitrum, allowing EU users to trade tokenized US stocks and ETFs as part of its real-world asset (RWA) expansion.

The company’s stock tokens mirror the prices of publicly traded US securities but don’t represent direct ownership of the underlying shares. Instead, they are structured as blockchain-based derivatives regulated under MiFID II (Markets in Financial Instruments Directive II), according to the company.  

The company also claims the stock tokens offer 24-hour market access, no hidden fees beyond a 0.1% FX charge and the ability to start investing with just 1 euro ($1.17).

However, the rollout has drawn scrutiny. In July, the Bank of Lithuania, which regulates Robinhood in the EU, requested clarification on how the tokens are structured. Tenev said the firm welcomes the review.

Robinhood deepens its crypto expansionRobinhood’s tokenization rollout came shortly after the brokerage firm launched micro futures contracts for Bitcoin (BTC), XRP (XRP) and Solana (SOL).

Earlier in May, the firm acquired Canadian crypto platform WonderFi in a $179 million deal, further expanding its global footprint. Robinhood has also been pushing for clearer tokenization regulations in the US, submitting a proposal to the Securities and Exchange Commission for a unified national framework governing RWAs.

Magazine: Back to Ethereum — How Synthetix, Ronin and Celo saw the light

If a quantum computer capable of breaking modern encryption were to come online today, Bitcoin would likely be under attack — and no one would know.

“Everything would look like legitimate access,” David Carvalho, CEO of post-quantum infrastructure company Naoris Protocol, told Cointelegraph. “When you think you’re seeing a quantum computer out there, it’s already been in control for months.”

“You wouldn’t even know,” he said.

Researchers at IBM, Google and government-backed laboratories are racing to close that gap, but the clock is ticking. The US National Institute of Standards and Technology (NIST) has begun approving post-quantum algorithms, while most public blockchains still rely on encryption designed in the 1980s.

For now, it’s a theoretical threat. But if the theory became reality, Bitcoin’s defenses would crumble faster than the network could react, Carvalho warned.

The first three finalized post-quantum encryption standards. Source: NISTHow a quantum attack could break BitcoinBitcoin’s core security depends on the Elliptic Curve Digital Signature Algorithm, or ECDSA, a cryptographic standard first proposed in 1985. The system allows users to prove ownership with a private key, while only the corresponding public key is visible to the network.

Using Shor’s algorithm, a sufficiently powerful quantum computer could theoretically recover a private key directly from a public one. That would allow attackers to access any wallet where the public key has been exposed onchain, such as those used in early Bitcoin (BTC) transactions.

“It would be impossible to prove a quantum computer did it because it derives legitimate access,” Carvalho said. “You’d just see those coins move as if their owners decided to spend them.”

Kapil Dhiman, CEO and founder of Quranium — a layer-1 blockchain startup focused on post-quantum security — warned that the earliest and most visible victims would be the oldest wallets.

“Satoshi’s coins would be sitting ducks,” he told Cointelegraph. “If those coins move, confidence in Bitcoin will shatter long before the system itself fails.”

In such a scenario, the blockchain would continue processing transactions normally. Blocks would be mined, and the ledger would remain intact, but ownership would have quietly changed hands.

The reality today is that more powerful GPUs and better algorithms make brute-force attacks slightly more efficient. However, ECDSA with Bitcoin’s 256-bit keys is still far beyond the reach of classical computing.

Bitcoin is behind TradFi in post-quantum encryptionWhile banks, telecom networks and government agencies are already testing post-quantum encryption, most major blockchains still rely on technology from the 1980s.

“All the blockchains have identified this vulnerability as a root cause,” Dhiman said, referring to the risk that current encryption methods like ECDSA could be broken by quantum computers.

Transitioning Bitcoin to a quantum-resistant model would require an overhaul of the network’s consensus rules that demands broad coordination among miners, developers and users.

Researchers have floated early proposals, including Bitcoin Improvement Proposal 360, which outlines potential pathways for adopting new cryptographic schemes, and the “Post Quantum Migration and Legacy Signatures Sunset” proposal, which phases out legacy signature schemes. Ethereum developers have also explored lattice-based signatures and other quantum-resistant options, though none have reached implementation.

Fear of quantum computing may be as destabilizing as the technology itself. Source: Jameson LoppIn traditional finance, the shift is already underway. The US NIST has approved algorithms, and JPMorgan has tested a quantum-safe blockchain in partnership with Toshiba. SWIFT has started offering post-quantum security training for its network.

“Traditional finance is actually ahead,” Carvalho said. “They have central control, budgets and a single authority that can push upgrades. Crypto doesn’t have that. Everything takes a consensus.”

Some newer blockchain projects are positioning themselves as quantum-ready from inception. Naoris Protocol, led by Carvalho, was mentioned in an independent proposal submitted to the US Securities and Exchange Commission that discussed post-quantum standards, while Dhiman’s Quranium uses the NIST-approved Stateless Hash-Based Digital Signature Algorithm. Meanwhile, Quantum Resistant Ledger is a blockchain built around XMSS hash-based signatures, a now-standardized NIST algorithm.

What happens if Bitcoin fails the quantum testFor the average Bitcoin holder, the primary concern is a sudden collapse in confidence, which could send prices plummeting and ripple through traditional markets, where institutional adoption of cryptocurrencies has been accelerating.

“There is a non-zero probability of it being out now. The consensus in the scientific, research and military communities is that it is not the case,” Carvalho said.

“However, it would not be the first time world-class cryptography had been broken without public knowledge,” he added, referring to the Enigma cipher.

Used by Nazi Germany during World War II, the Enigma cipher was considered unbreakable at the time. But cryptanalysts led by Alan Turing and his team at Bletchley Park quietly cracked it. The Allies kept the breakthrough a secret so that Germany would continue using the cipher.

Enigma was cracked, but nobody knew. Source: National Security Agency“When you think you’re seeing a quantum computer, it’s already been in control for months,” Carvalho warned.

But experts remain optimistic that quantum-secure blockchain systems are achievable and that the industry is attempting to align with standards already being adopted in traditional finance.

“Quantum-secure systems are possible,” said Dhiman. “We just need to start building them before the threat becomes real.”

For now, quantum threats remain theoretical. Bitcoin’s encryption holds strong, and computers capable of breaking it exist only on paper.

Magazine: Bitcoin vs. the quantum computer threat: Timeline and solutions (2025–2035)